List/Grid

Cancer Subscribe to Cancer

Described novel regulator of protein inactive in over 50 percent of human tumors

Described novel regulator of protein inactive in over 50 percent of human tumors

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona have discovered the interaction between HERC2 proteins with another protein called p53 that is inactivated in more than half of human tumors. The study results were published in the Journal of Biological Chemistry. Regulation of the activity of p53 by HERC2 The team of José Luis Rosa, at the growth factors and cell differentiation research group at IDIBELL studies the molecular mechanisms of HERC family proteins. Continue reading

Described novel regulator of protein inactive in over 50 percent of human tumors

Described novel regulator of protein inactive in over 50 percent of human tumors

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona have discovered the interaction between HERC2 proteins with another protein called p53 that is inactivated in more than half of human tumors. The study results were published in the Journal of Biological Chemistry. Continue reading

New technique maps life’s effects on our DNA: Powerful single-cell technique to study environmental effects on DNA

New technique maps life’s effects on our DNA: Powerful single-cell technique to study environmental effects on DNA

Researchers at the BBSRC-funded Babraham Institute, in collaboration with the Wellcome Trust Sanger Institute Single Cell Genomics Centre, have developed a powerful new single-cell technique to help investigate how the environment affects our development and the traits we inherit from our parents. Continue reading

Genetic cause of common breast tumors found

Genetic cause of common breast tumors found

A multi-disciplinary team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, and Singapore General Hospital have made a major breakthrough in understanding the molecular basis of fibroadenoma, one of the most common breast tumors diagnosed in women. Continue reading

Metabolic enzyme stops progression of most common type of kidney cancer

Metabolic enzyme stops progression of most common type of kidney cancer

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. Continue reading

Scientists map one of most important proteins in life — and cancer

Scientists map one of most important proteins in life — and cancer

Scientists reveal the structure of one of the most important and complicated proteins in cell division — a fundamental process in life and the development of cancer — in research published in Nature . Continue reading

Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients

Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA , a theme issue on HIV/AIDS. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent Continue reading

Targets for immunotherapy in early-stage breast cancer

Targets for immunotherapy in early-stage breast cancer

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials Continue reading

Causes of death shifting in people with HIV

Causes of death shifting in people with HIV

HIV-positive adults in high income countries face a substantially reduced risk of death from AIDS-related causes, cardiovascular disease, and liver disease compared with a decade ago, according to a large international study published in The Lancet. The study which involved nearly 50,000 HIV-positive adults receiving care and antiretroviral therapy (ART) at more than 200 clinics across Europe, USA, and Australia found that overall death rates have almost halved since 1999, while deaths due to AIDS-related causes and cardiovascular disease have declined by around 65% and liver-related deaths by more than 50%. Although deaths from most causes declined over the study period, there was no reduction in death rates from non-AIDS cancers which remained stable over time (1.6 deaths per 1000 years 1999-2000 to 2.1 in 2009-2011) Continue reading

Drug’s effect on Alzheimer’s may depend on severity of disease

Drug’s effect on Alzheimer’s may depend on severity of disease

A cancer drug that has shown promise against Alzheimer’s disease (AD) in mice and has begun early clinical trials has yielded perplexing results in a novel mouse model of AD that mimics the genetics and pathology of the human disease more closely than any other animal model. The drug, bexarotene, was found to reduce levels of the neurotoxic protein amyloid-beta in experimental mice with late-stage Alzheimer’s but to increase levels during early stages of disease. The finding, by researchers at the University of Illinois at Chicago College of Medicine, was reported July 16 at the Alzheimer’s Association International Conference in Copenhagen by Mary Jo LaDu, who in 2012 developed a transgenic mouse that is now regarded as the best animal model of the human disease. Continue reading